Latest Ratios: P/E Ratio -8.1x · EV/EBITDA N/A · ROE -30.7%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $591M | $538M | $349M | $148M | $572M | $984M | — | — |
| Enterprise Value | $576M | $522M | $329M | $130M | $549M | $689M | — | — |
| P/E Ratio → | -8.06 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.55 | 2.53 | 1.44 | 0.53 | 1.75 | 2.57 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | -98.3% |
| Operating Margin | — | — | — | — | — | — | — | -228777.0% |
| Net Profit Margin | — | — | — | — | — | — | — | -245443.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -30.7% | -30.7% | -19.1% | -22.1% | -17.8% | -19.2% | — | — |
| ROA | -29.2% | -29.2% | -18.3% | -21.2% | -17.3% | -16.6% | -45.2% | -2274.4% |
| ROIC | -28.4% | -28.4% | -19.4% | -20.8% | -25.9% | -73.1% | — | — |
| ROCE | -34.8% | -34.8% | -23.8% | -25.6% | -18.9% | -17.1% | -56.0% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.07 | -0.08 | -0.07 | -0.07 | -0.77 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($17M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.14 | 17.14 | 29.31 | 29.58 | 31.10 | 72.96 | 15.55 | 0.02 |
| Quick Ratio | 17.14 | 17.14 | 29.31 | 29.58 | 31.10 | 72.96 | 15.55 | 0.02 |
| Cash Ratio | 16.84 | 16.84 | 29.01 | 29.29 | 30.66 | 72.70 | 15.49 | 0.02 |
| Asset Turnover | — | — | — | — | — | — | — | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $57M | $57M | $56M | $56M | $46M | $27M | $27M |
Includes 30+ ratios · 7 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DSGN stock.
Design Therapeutics, Inc.'s current P/E ratio is -8.1x. This places it at the 50th percentile of its historical range.
Design Therapeutics, Inc.'s return on equity (ROE) is -30.7%. The historical average is -21.8%.
Based on historical data, Design Therapeutics, Inc. is trading at a P/E of -8.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Limited cash runway against burn
Metrics are mathematically derived from official filings.
Negative Earnings Leave Multiples Uninformative
With trailing P/E at -9.16 and P/B at 2.91 per reported figures, DSGN's earnings-based multiples are not meaningful, leaving book value and the equity base as the only usable reference points for an unprofitable pre-revenue company.
The negative P/E reflects a loss-making profile rather than a valuation signal, so comparison against own history or peers should rely on P/B and cash-based measures instead. The P/B of 2.91 sits above the peer FULC at 0.68, which suggests the market is paying a premium over reported book equity, likely reflecting the value placed on the GeneTAC platform and pipeline optionality rather than current earnings. Investors should monitor whether this premium narrows as cash declines and the balance sheet shrinks.
Returns Deteriorating as Losses Widen
Per reported ratios, ROE moved from -4.4% in 2024Q2 to -10.0% in 2026Q3 and ROIC from -4.9% to -8.8%, indicating that capital is being consumed at a faster pace as operating losses scale with R&D spend.
The decline in ROE and ROIC reflects growing losses against a shrinking equity base, which is the mechanical outcome of a development-stage company funding clinical programs from its balance sheet. Because the company has no revenue, these returns are driven entirely by the expense base, and ROIC trends here tell us about burn relative to capital rather than about operating efficiency. The trajectory suggests capital is decaying rather than compounding, and this warrants monitoring alongside any future financing that could reset the equity base.
Current Ratio Masks Thin Cash Coverage
Reported current ratio of 16.78 in 2026Q3, down from 41.42 in 2024Q2, looks robust on the surface, but based on reported figures cash of $15.3M covers only about one quarter of free cash flow burn near -$15.4M.
The high current ratio is a function of a small liability base relative to current assets, but the ratio itself does not reveal how quickly those assets are consumed by operations. The steady decline from 41.42 to 16.78 across ten quarters indicates current assets are being drawn down faster than current liabilities are growing. Under a stress scenario where financing is delayed, the position appears to offer limited headroom, and investors should monitor the next financing event closely.
Minimal Debt Reflects Equity-Funded Model
Debt-to-equity of 0.01 across all reported quarters, with interest coverage not reported, indicates that DSGN's development is funded almost entirely through equity, shifting the risk from creditor covenants to dilution.
Leverage is not the binding constraint here because the company carries negligible debt relative to its equity base, so covenant and refinancing risk appears low on reported figures. The relevant risk is instead the dilution that equity funding implies for existing shareholders as cash is consumed. Interest coverage is unavailable given the absence of meaningful interest expense, so the analysis rests on the debt ratio alone.
Misapplied Current Ratio Obscures Runway
The current ratio is the metric most commonly misapplied to this pre-revenue model, because it treats the company as a going concern with stable operations when reported burn suggests a much shorter effective runway.
The current ratio ignores the rate of cash consumption and implicitly assumes current assets will be available to meet obligations over a normal operating cycle, which does not fit a company with no revenue and quarterly free cash flow of roughly -$15.4M. A more useful alternative is months of runway, calculated as cash divided by quarterly burn, which on reported figures points to about one quarter of coverage. Investors should weight runway and financing timing above the headline current ratio when assessing this business.